Molecular Prognostic Test for Sepsis for use in Point of Care Setting

Diagnosis of SIRS & sepsis and identification of patients likely to progress to severe sepsis or septic shock is challenging due to a lack of definitive diagnostic tests. This project aims to identify biomarker panels for diagnosis and prognosis of SIRS, sepsis and likely progression to severe sepsis from patient host biomarkers identified in previously published studies. These will be comprehensively assessed in a combined study using temporally retrieved blood samples from a new cohort of SIRS & sepsis patients and identified using the sophisticated ANN analysis methods of NTU. Validated panels of markers will be used to build new diagnostic and prognostic ‘point of care’ and laboratory-based tests on the Atlas Genetics’ and Randox Laboratories’ platforms, which will be used to inform patient treatment and long-term care. This study is only possible through the expertise and unique collaboration between the commercial partners Atlas and Randox, the HPA, NTU, CCA and SARTRE.